Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT04809181
Phase
PHASE2
Status
Unknown

Conditions

  • Hematologic Malignancy
  • Stem Cell Transplant Complications

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell transplantation for AML/MDS.

Key Dates

Start date
Mar 19, 2021
Status verified
Feb 2023
Primary completion
Mar 19, 2024
Completion
Mar 19, 2026

Study Design

Enrollment
95 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
    MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation

Primary Outcome Measure

relapse-free survival [ Time Frame: 2 year ]

Central Contacts

Related Studies